In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 206 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI continuam a encontrá-las. Abra sempre a notícia original e fale com o seu médico antes de tirar conclusões sobre o seu caso. Última recolha: 17 nov 2026, 21:48.
Tuesday, November 17
Tocantins passa a oferecer daratumumabe contra o mieloma na rede estadualO Cafezinho · 15:55 TreatmentsPTSecretaria de Saúde do Tocantins padronizou o daratumumabe e a versão subcutânea já é aplicada no Hospital Geral de Palmas, segundo o NC News.
Monday, 16/11
Ben Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026Oncodaily · 18:05 InvestigaçãoBen Derman։ Top 10 Myeloma Abstracts to Be Presented at ASH 2026 / ASCO, ASH 2026, Ben Derman, cancer, CAR-T, DARA, Daratumumab, Lenalidomide, Mount Sinai,
The Tocantins State Government is expanding oncological treatment by incorporating a high-cost medication.Agência Tocantins (Brazil) · 14:27 Access and public healthBrazilPTThe first administration of daratumumab was performed on a patient with multiple myeloma attended at the HGP.
Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System AnalysisOncodaily · 11:23 TratamentosTeclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA
Thursday, November 12th
EXCALIBER-RRMM Trial Results: MRD Negativity and Progression-Free Survival in Relapsed/Refractory Multiple MyelomaCancerNetwork (EUA) · 13:13 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael and Dr. Paul Richardson discuss findings from the phase 3 EXCALIBER-RRMM trial, which compared iberdomide plus daratumumab and dexamethasone with bortezomib plus daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
Monday, November 9th
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneASCO Publications (Reino Unido) · 21:20 Doentes e associaçõesReino Unido
Friday, November 6th
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Terça, 27/10
EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myelomaMyeloma Patients Europe (Europa) · 10:49 Acesso e saúde públicaEuropaOn 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together with pomalidomide, for myeloma patients who have received at least one previous line of treatment. The CHMP is…
Terça, 20/10
CHMP backs TALVEY plus daratumumab for earlier myeloma usePharmaTimes (Reino Unido) · 07:00 Acesso e saúde públicaReino UnidoRecommendation supports second-line combination option
Sexta, 16/10
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myelomaGlobeNewswire (Internacional) · 07:00 Acesso e saúde públicaInternacionalIf approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple...
Quinta, 08/10
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...Business Wire (Internacional) · 07:00 TratamentosInternacional
Quarta, 30/09
Overview | Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable | GuidanceNICE website (Reino Unido) · 07:00 TratamentosReino Unido
Segunda, 24/08
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple MyelomaTargeted Onc (EUA) · 07:00 Acesso e saúde públicaEUAThe iberdomide-daratumumab-dexamethasone regimen was approved based on superior MRD negativity rate vs standard of care in relapsed/refractory multiple myeloma.
Sexta, 21/08
- European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of careGlobeNewswire (Internacional) · 07:00 TratamentosInternacional
Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of...
Notícias com mais de 90 dias: só o título e o link para a fonte.
Pay attention to old news. Marked as. about 1 year 2 years 5 years 10 years You may also want to check that the information is still up to date: treatments, approvals and prices change quickly. Always confirm with your hematology team.
Access and public health
- The U.S. FDA grants accelerated approval to the first CELMoD therapy from Bristol Myers Squibb, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Business Wire · 13/08/2026
- The U.S. FDA grants accelerated approval to the CELMoD therapy from Bristol Myers Squibb, ZENBEXUS™, in combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for patients with multiple myeloma, from the first relapse. ↗ · Bristol Myers Squibb · August 13, 2026
- FDA approves iberdomide with daratumumab and dexamethasone for relapsed/refractory myeloma ↗ · OncLive · 13/08/2026
- Johnson & Johnson receives approval from Anvisa for TECVAYLI® (teclistamabe) in combination with DALINVI® (daratumumab) subcutaneous (SC) for relapsed or refractory multiple myeloma, expanding treatment options available for patients ↗ · PR Newswire · 18/06/2026
- FDA Approves Teclistamab Plus Subcutaneous Daratumumab for Relapsed/Refractory Multiple Myeloma · OncLive · 05/03/2026
- FDA approves quadruplet with daratumumab in multiple myeloma without indication for transplant ↗ · Oncology News Central · 28/01/2026
- FDA approves daratumumab and hialuronidase in combination with VRd in multiple myeloma ↗ · The ASCO Post · January 27, 2026
- Johnson & Johnson is seeking approval from the EMA for the combination teclistamab–daratumumab. · PharmaTimes · 06/01/2026
- Darzalex (daratumumab) authorised for use in an inpatient setting ↗ 4 years ago · www.netfarma.pt · 19/04/2022
- FDA approves new use of daratumumab in multiple myeloma ↗ 9 years · National Cancer Institute (.gov) · 09/12/2016
- DARZALEX® (daratumumab) approved by the FDA: the first human monoclonal antibody anti-CD38 available to treat multiple myeloma ↗ 11 years · Johnson & Johnson · November 16, 2015
Patients and associations
- Belantamab mafodotina, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in relapsed/refractory multiple myeloma: updated overall survival and efficacy from the phase 3 DREAMM-7 trial ↗ about 1 year · International Myeloma Society · January 30, 2025
- Phase 3 Trial IFM2017-03: scheme with less dexamethasone, with daratumumab and lenalidomida, for frail patients with newly diagnosed multiple myeloma ↗ about 1 year · International Myeloma Society · January 30, 2025
Treatments
- The new TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hialuronidase-fihj) demonstrate the power of a bispecific combination in relapsed or refractory multiple myeloma at the start of treatment. ↗ · PR Newswire · 06/13/2026
- Teclistamab with daratumumab in relapsed or refractory multiple myeloma ↗ · The New England Journal of Medicine · 10/12/2025
- Project information | Daratumumab for treating high-risk smouldering multiple myeloma [D10] | Guidance ↗ 2 years · NICE website · 10/04/2024
- Daratumumab, bortezomib, lenalidomide and dexamethasone in multiple myeloma ↗ 2 years · The New England Journal of Medicine · 12/12/2023
- Summary | Daratumumab with lenalidomide and dexamethasone in the treatment of multiple myeloma who are not treated when transplantation is not possible | Recommendation ↗ 3 years · NICE website · 25/10/2023
- Teclistamab with daratumumab in multiple myeloma in relapse or refractory after one or more treatments (ID6201) ↗ 4 years ago · NICE website · 24/10/2022
- Summary | Daratumumab alone in multiple myeloma in relapse and refractory | Recommendation ↗ 4 years ago · NICE website · 13/04/2022
- Daratumumab in combination for multiple myeloma who is not treated when transplant is feasible ↗ 4 years ago · NICE website · 02/02/2022
- Daratumumab subcutaneous: another advancement in the treatment of multiple myeloma ↗ 5 years · Afya | Home · November 30, 2020
- Genmab announces submission of European approval request for daratumumab in refractory multiple myeloma ↗ 8 years · Genmab · 20/08/2018
- Official website for patients | DARZALEX® and DARZALEX FASPRO® (daratumumab) ↗ 11 years · edge.prnewswire.com · 17/11/2015
